Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).

Slides:

Advertisements

Similar presentations

An Alternative to Data Imputation in Analgesic Clinical Trials David Petullo, Thomas Permutt, Feng Li Division of Biometrics II, Office of Biostatistics.

Advertisements

From: An open day in the metric space

Copyright © 2003 American Medical Association. All rights reserved.

Fig. 1 Flow chart of the COBRA-light trial and its extension study

Figure 2. Quality of life (QOL) scores for functional scale items

Fig. 1 Graphical representation

Patients in the no test scenario all enter the model at A, while patients in the test scenario enter the model at either A or B dependent upon test result.

Figure 2. CONSORT flow diagram.

Fig 1 Trends in organ donors in the UK, 2000–10

Figure 1 Cumulative chance of pregnancy according to age at initiation of pregnancy seeking. The curves were drawn based on the following assumptions:

Test characteristics of MRI-detected inflammation for the development of arthritis in CSA patients (A) and RA in UA patients (B) during 1-year follow-up.

Error bars represent the mean (s.e.).

Patients were considered not in MDA (MDA−) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA+) with a score of 5, 6 or 7 points.

pSS: primary SS; Scl: scleroderma.

Figure 1. Selection of papers.

Fig. 1 Flow chart of study selection

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

Fig. 1 Proportion of study participants with ideal Cardiovascular Health Metrics by self-rated health. Ideal category of Cardiovascular Health Metrics.

Fig 1 Respiratory support escalation strategies for study patients

Fig 1 Perfusion index values at different time intervals in patients with successful and failed blocks. A reference line at PI 3.3 is provided. Horizontal.

From: A European Disease

Fig. 1 Selection of patients

Fig. 1 Flow diagram of patient selection and study design.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Fig 1 Coding search and excluded records.

Figure 1 Flow of data processing

Figure 1: Logistic regression showing association of prescribing provider and patient panel characteristics with occurrence of a hospitalization or ED.

Fig 1 Percentage of patients in the combined modified intent-to-treat population with efficacy endpoints accounting specifically for nausea, by treatment.

Figure 1 Pulmonary vein anatomical locations

FIGURE 1 Trial profile. The safety population was defined as all randomly assigned patients who received at least one dose of study drug. All patients.

Figure 1. Impact ratings for prospective memory lapses for younger (~age 30), middle-age (~age 50), and older (~age 65) adults. From: Daily Memory Lapses.

Figure 6. RRs for clinical cure rates stratified by different diseases

Figure 1. Percentage of participants in each group (holocaust survivors, prewar immigrants, and postwar immigrants) by the main coded strategies. From:

Figure 3. Changes from baseline in activated CD4+ T cells (% CD4+CD25+) during the 52-week intervention period in the.

Copyright © 2004 American Medical Association. All rights reserved.

Thadhani et al. Am J Nephrol 2017;45:40-48 (DOI: / )

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Patients included in linear extrapolation and observed/last observation carried forward analyses at week 48. Patients who were rescued or discontinued.

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.

Figure 1 Study flow diagram and definition of clinical response

(A) Mean (s.d.) ... (A) Mean (s.d.) baseline values for study variables for patients with and without tophi. (B) Baseline (s.d.) quality of life scores.

(A) mSchober in DESIR; (B) mSchober in SPACE; (C) LSF ...

Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.

Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.

bDMARD: biologic DMARD.

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Fig. 1 Mean change from baseline in ANC ± s. e

(A, B) Upon presentation large, scaly, annular plaques with well-defined, erythematous, raised ... (A, B) Upon presentation large, scaly, annular plaques.

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

High IFN-α levels were found in patient’s serum, and ...

Fig. 1 Subacute cutaneous lupus erythematous at the lower limbs

Fig. 1 Flow chart of included patients for analyses

Rats were treated for 21 days ...

Fig. 1 Flow chart for selection of study subjects

Prevalence and distribution of ...

ACR responder rates in patients receiving CZP from Week 0, stratified by prior anti-TNF exposure (A−C) and the proportion of patients receiving CZP from.

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Percentage of patients with RA achieving DAS28(CRP)<2

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Fig. 1 Schematic subcategorization of AAV in three clinically relevant disease categories defined by clinical ... Fig. 1 Schematic subcategorization of.

(A, B) Upon presentation large, scaly, annular plaques with well-defined, erythematous, raised ... (A, B) Upon presentation large, scaly, annular plaques.

The percentage of patients with baseline BSA ≥ 3% in the ITT population who achieved (a) PASI 75, (c) PASI 90, and (e) PASI 100 during the 24-week double-blind.

Study design. Study design. Patients who completed the 8-week induction study and achieved clinical response-100 (decrease in Crohn's disease activity.

Presentation transcript:

Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D). Reasons for non-response in panels B and D were determined sequentially in the order shown from left to right. The analyses are based on the intention-to-treat population, which included all patients that participated in a trial and received at least one dose of study drug. For trial 1, n = 379 in the placebo arm and n = 759 in the combined treatment arms. For trial 2, n = 376 in the placebo arm and n = 748 in the combined treatment arms. The combined treatment arms included an every 2 week and an every 4 week dose arm in each trial. From: Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index Rheumatology (Oxford). Published online October 17, 2017. doi:10.1093/rheumatology/kex368 Rheumatology (Oxford) | © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Proportion of patients with active disease manifestations at baseline by the SLEDAI organ system (A and C) and specific SLEDAI disease manifestation (B and D) for the combined treatment populations in trial 1 (A and B) and trial 2 (C and D). Individual SLEDAI disease manifestations in panels B and D are shown for the three highly prevalent organ systems (mucocutaneous, musculoskeletal and immunologic) and are colour coded to their organ system in panels A and C. Percentages are calculated from the baseline values for the combined intention-to-treat population (placebo plus both dose arms) prior to first administration of the study drug (n = 1138 in trial 1 and n = 1124 in trial 2). From: Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index Rheumatology (Oxford). Published online October 17, 2017. doi:10.1093/rheumatology/kex368 Rheumatology (Oxford) | © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Response rate over time in the placebo population for the four high-prevalence SLEDAI clinical disease manifestations [(A) arthritis; (B) rash; (C) alopecia; (D) mucosal ulcer]. Each analysis represents the subpopulation of placebo patients that had the disease manifestation at baseline by the SLEDAI. Patients were considered responders if the disease manifestation had resolved at the indicated visit. At baseline, the analysis included arthritis (n = 306 and 313), rash (n = 270 and 245), alopecia (n = 235 and 209) and mucosal ulcer (n = 135 and 107) for trials 1 and 2, respectively. Analyses were conducted using observed data at each visit with no imputation for missing data or dropouts. From: Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index Rheumatology (Oxford). Published online October 17, 2017. doi:10.1093/rheumatology/kex368 Rheumatology (Oxford) | © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Baseline prevalence of renal, vascular and CNS disease as measured by the SLEDAI organ system in the intention-to-treat (ITT) population (A and C) and SRI-5 response rate in placebo patients with renal, vascular and CNS disease at week 52 (B and D) in trial 1 (A and B) and trial 2 (C and D). Renal, vascular and CNS organ systems were investigated due to high SLEDAI point values when calculating SRI-5 response rates. Few patients had activity in more than one of these organ systems at baseline, as indicated in panels A and C. SRI-5 response rates in placebo patients with renal, vascular or CNS disease were greater than the response rate in the ITT populations. SRI-5 response rates are confined to placebo and based on ITT (n = 379 and 376), renal (n = 42 and 30), vascular (n = 30 and 26) and CNS (n = 6 and 7) in trials 1 and 2, respectively. From: Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index Rheumatology (Oxford). Published online October 17, 2017. doi:10.1093/rheumatology/kex368 Rheumatology (Oxford) | © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Cumulative proportion of placebo patients with an increase in average daily prednisone use of ≥ 2.5 mg/day between visits during the first 24 weeks in trials 1 and 2. Analysis was limited to placebo patients during the first 24 weeks when increases in steroids were allowed. The number of patients at randomization was 379 and 376 in trials 1 and 2, respectively. From: Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index Rheumatology (Oxford). Published online October 17, 2017. doi:10.1093/rheumatology/kex368 Rheumatology (Oxford) | © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

SRI-5 response rate at week 24 in the subset of placebo patients that were taking corticosteroids at baseline in (A) trial 1 and (B) trial 2. Placebo patients were separated into two populations for the analysis: patients with stable corticosteroids that did not increase >2.5 mg/day between visits and patients that had protocol permitted increases in corticosteroids, defined as a ≥ 2.5 mg/day increase in average daily prednisone use between visits during the first 24 weeks. The number of patients in each analysis is defined as the number achieving SRI-5 at week 24/total number of patients in the subset. From: Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index Rheumatology (Oxford). Published online October 17, 2017. doi:10.1093/rheumatology/kex368 Rheumatology (Oxford) | © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com